Navigation Links
Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
Date:10/12/2007

RALEIGH, N.C., Oct. 12 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotechnology industries, today announced that Ben Bonifant, Vice President of the firm's Business Development (BD) practice, will moderate two workshops at the Licensing Executive Society (LES) Annual Meeting. The event will be held on October 14-18, 2007 at the Vancouver Convention and Exhibit Centre in Vancouver, Canada.

Mr. Bonifant's first workshop, titled "Building the Business Development Function from the Ground Up at a Growth-Orientated Pharmaceutical Company," will discuss the three key areas of building a first-rate BD function: strategy development, assessment and action, and opportunity generation. The workshop is scheduled for Tuesday, October 16 at 3:45 pm and will include participation from four senior BD executives representing global pharmaceutical and biotech companies.

Mr. Bonifant's second workshop, titled "Understanding the Regional Differences in Deal Making," will be held on Wednesday, October 17 at 2:00 pm. Mr. Bonifant, along with three pharmaceutical and biotech BD and licensing executives, will discuss critical considerations for BD professionals when executing regional deals, as well as country-specific differences for evaluating licensing opportunities. Delegates attending this session will hear firsthand case studies from companies that have successfully executed regional deals across various therapeutic areas.

Mr. Bonifant has been a management consultant for nearly 15 years, helping leaders of global pharmaceutical and biotech organizations and decision makers in large private equity funds. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals, and he is a frequent guest lecturer at some of the nation's premier universities. Mr. Bonifant earned an MBA from the Stanford Graduate School of Business.

For mor
'/>"/>

SOURCE Campbell Alliance
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biomedical Alliance about more than stem cells
2. Doyle seeks $2.5M for biomedical alliance
3. Alliance looks to create the right chemistry in SE Wisconsin
4. Biomedical alliance marks first full year
5. New alliance to provide Wi-Fi network for City of Madison
6. Budget axe could cut SE Wisconsin tech alliance funding
7. Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
8. Milwaukee research alliance sees need for incubator
9. University alliance gets $2.5 million to encourage minorities in science and technology
10. Suite Scheduler Announces Alliance with Ice Technologies
11. Alliance Brings E-Business Technologies to Wisconsin Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 2010 Shire plc (LSE: SHP,NASDAQ: SHPGY ) the global specialty biopharmaceutical company, announces,results for the three months to March 31, 2010 . ... ... $718 million ... Total revenues ...
... , April 29, 2010 According to ... by,MarketsandMarkets ( http://www.marketsandmarkets.com ), The global oncology,biomarker market is ... 2009 to $9.5,billion in 2014 at a ... Oncology,Biomarkers Market report analyzes the oncology biomarkers diagnostics and,discovery ...
... also known as hypertension, is a serious health risk factor ... the molecular basis of the disease remains poorly understood. ... ( www.genome.org ), scientists have sequenced the genome of ... variants that will help researchers to understand causes of the ...
Cached Biology Technology:Shire's Replenished Portfolio Drives Excellent Quarterly Performance 2Shire's Replenished Portfolio Drives Excellent Quarterly Performance 3Shire's Replenished Portfolio Drives Excellent Quarterly Performance 4Shire's Replenished Portfolio Drives Excellent Quarterly Performance 5Shire's Replenished Portfolio Drives Excellent Quarterly Performance 6Shire's Replenished Portfolio Drives Excellent Quarterly Performance 7Shire's Replenished Portfolio Drives Excellent Quarterly Performance 8Shire's Replenished Portfolio Drives Excellent Quarterly Performance 9Shire's Replenished Portfolio Drives Excellent Quarterly Performance 10Shire's Replenished Portfolio Drives Excellent Quarterly Performance 11Shire's Replenished Portfolio Drives Excellent Quarterly Performance 12Shire's Replenished Portfolio Drives Excellent Quarterly Performance 13Shire's Replenished Portfolio Drives Excellent Quarterly Performance 14Shire's Replenished Portfolio Drives Excellent Quarterly Performance 15Shire's Replenished Portfolio Drives Excellent Quarterly Performance 16Shire's Replenished Portfolio Drives Excellent Quarterly Performance 17Shire's Replenished Portfolio Drives Excellent Quarterly Performance 18Shire's Replenished Portfolio Drives Excellent Quarterly Performance 19Shire's Replenished Portfolio Drives Excellent Quarterly Performance 20Shire's Replenished Portfolio Drives Excellent Quarterly Performance 21Shire's Replenished Portfolio Drives Excellent Quarterly Performance 22Shire's Replenished Portfolio Drives Excellent Quarterly Performance 23Shire's Replenished Portfolio Drives Excellent Quarterly Performance 24Shire's Replenished Portfolio Drives Excellent Quarterly Performance 25Shire's Replenished Portfolio Drives Excellent Quarterly Performance 26Shire's Replenished Portfolio Drives Excellent Quarterly Performance 27Shire's Replenished Portfolio Drives Excellent Quarterly Performance 28Shire's Replenished Portfolio Drives Excellent Quarterly Performance 29Shire's Replenished Portfolio Drives Excellent Quarterly Performance 30Shire's Replenished Portfolio Drives Excellent Quarterly Performance 31Shire's Replenished Portfolio Drives Excellent Quarterly Performance 32Shire's Replenished Portfolio Drives Excellent Quarterly Performance 33MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 2MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 3MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 4
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Researchers from LSU Health Sciences Center New Orleans ... of Child Health and Human Development (NICHD), Harvard School ... Medical School, have found for the first time that ... a week prior to pregnancy appears to significantly elevate ...
... - The inaugural Global Conference on Systems & ... Washington, DC, focuses on the convergence of complex large-scale ... The goal of the conference ... targeted complex systems, examined by domain, each successive year. ...
... early bird registration rates and register online now for ... WHAT: IOF WCO-ECCEO10 is a joint ... European Society for Clinical and Economic Aspects of Osteoporosis ... the world are expected to attend. The exciting scientific ...
Cached Biology News:Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: